Faculty
Skolnik, Paul R., M.D.
Medical School: University of Pennsylvania School of Medicine
Residency training: Hospital of the University of Pennsylvania
Fellowship training: Massachusetts General Hospital
Dr. Skolnik is Chief of the Section of Infectious Diseases, and Director of the Center for HIV/AIDS Care and Research (CHACR) at Boston University Medical Center (BUMC). The CHACR oversees all the clinical care, clinical research, basic research, and teaching at BUMC. He is Professor of Medicine and attending physician at BUMC. He is board certified in both internal medicine and infectious diseases. Dr. Skolnik’s current basic research interests include HIV-related innate immune responses in the lung, and modeling of cytokine and chemokine networks in the lung. Patient-derived samples are used in these studies whenever possible to most closely mirror the in vivo situation. Dr. Skolnik conducts trials of investigational immunotherapeutic and antiretroviral drug therapies for HIV infection, and has expertise in clinical research design and methodology. He is site leader for the AIDS Clinical Trials Group (ACTG) at Boston University Medical Center. Dr. Skolnik directs the Massachusetts Department of Public Health (MDPH)- and CDC-funded comprehensive HIV and HCV testing and counseling programs at BUMC, serves as director for MDPH-funded linkage to care and early intervention programs, and is co-PI for a CDC/HRSA retention in care grant. Dr. Skolnik has a substantial record of serving as mentor for successful basic and clinical research trainees on NIH-funded T32 training grants and K08 awards.
Barlam, Tamar Foster, M.D.
Medical School: University of Rochester School of Medicine and Dentistry
Residency training: Presbyterian University of Pennsylvania Medical Center
Fellowship training: Columbia Presbyterian Medical Center
Dr. Barlam oversees programs in antimicrobial stewardship at Boston Medical Center and the Boston VA Healthcare System. She is responsible for overseeing antimicrobial usage with the goal of optimizing patient outcomes while minimizing antibiotic resistance and excessive costs. Within these clinical activities, she will be conducting studies to define and, if possible, prioritize the most effective prescribing interventions, develop antibiotic stewardship strategies for smaller community and rural hospitals with limited resources, and define which educational tools best teach appropriate antimicrobial usage and improve clinical practice.
Barry, M. Anita, M.D., M.P.H.
Medical School: Columbia University College of Physicians and Surgeons
Residency training: Boston City Hospital
Fellowship training: Boston University School of Medicine
MPH: Boston University
Dr. Barry is the Director of Communicable Disease Control for the Boston Public Health Commission (the city’s health authority). In that role, she is responsible for surveillance and control of all communicable diseases within Boston. Current research activities are related to waterborne illnesses, and surveillance for and response to bioterrorism and other mass casualty infectious diseases events. She is the Medical Director of the BPHC Tuberculosis Clinic located at Boston Medical Center.
Bica, Ioana, M.D.
Medical School: “Carol Davila” University, Bucharest, Romania
Residency training: University of Massachusetts Memorial Health Care
Fellowship training: Tufts-New England Medical Center, Boston
Dr. Bica is an infectious diseases physician and focuses on clinical infectious diseases and the clinical care of HIV-infected patients, and patients with hepatitis C, with specific expertise in the care of HIV-HCV coinfected individuals. Her current research activities are related to HIV infection, and hepatitis C coinfection.
Cotton, Deborah, M.D., M.P.H.
Medical School: Boston University School of Medicine
Residency training: Beth Israel Hospital, Boston
Fellowship training: National Institute of Allergy and Infectious Diseases National Cancer Institute
MPH: John Hopkins University
Dr. Deborah Cotton is Professor of Medicine at the Boston University School of Medicine and Professor of Epidemiology at the Boston University School of Public Health. From 1998-2001, Dr. Cotton served as Assistant Provost for Clinical Research for the Boston University Medical Campus and Director, Office of Clinical Research, and from 2001-2004 was Chief of the Medical Service of the VA Boston Healthcare System. She is currently Chief Medical Officer of the Clinton Foundation HIV/AIDS Initiative, which works in over twenty countries in sub-Saharan Africa, Asia and Latin America to promote the prevention and treatment of HIV infection by providing low-cost drugs and diagnostics, clinical training and mentoring, clinical operations scale up, and national guideline development. Dr. Cotton’s research concerns the clinical epidemiology of infectious diseases, especially HIV/AIDS. She is currently the Principal Investigator of CHARM, a large cohort study of hepatitis C/HIV co infection funded by NIDA. She is also the Director of the Consortium for Strategic Operations Research at the Clinton Foundation, which is supported by a grant from the Bill and Melinda Gates Foundation. Dr. Cotton has served on numerous national committees including the FDA Antiviral Advisory Committee (member and chair), the Board on Health Sciences Policy of the Institute of Medicine, and the NIH Office of AIDS Research Advisory Council. She currently serves on the National and Global Public Health Committee of the Infectious Diseases Society of America, and the Executive Committee of the Forum on Collaborative HIV Research.
Fuller, Jon D., M.D.
Medical School: University of California, San Diego
Residency training: University of California, San Francisco (SF General Hospital, Family Medicine)
Dr. Fuller has been a clinical provider in the Boston Medical Center HIV program since 1987. He manages the Center for HIV/AIDS Care and Research Thursday AIDS Conference Series, and coordinates elective rotations of medical students and residents through the Center for Infectious Diseases. As a Jesuit priest, he is particularly interested in how HIV prevention approaches can be analyzed and supported from the context of Catholic moral theology, and he serves as a consultant to international Catholic development and relief agencies on HIV-related policies.
Ganley-Leal, Lisa, Ph.D.
Ph.D.: University of Connecticut Health Center
Postdoctoral training: Centers for Disease Control and Prevention, Boston University Medical Center
Dr. Lisa Ganley-Leal’s primary research focus is on defining immune correlates of protection in human schistosomiasis including mechanisms by which IgE and IgE receptors play a role in generating immunity. Her studies in this area are in collaboration with the Centers for Disease Control and Prevention, Kenya Medical Research Institute and the University of Georgia. She is currently collaborating with the Schistosomiasis Control Program in Burkino Faso. To establish a mechanistic understanding of field clinical data, her laboratory developed a model system using human tissue B cells to recapitulate the inflammatory milieu of parasitic helminth disease. In addition, Dr. Ganley-Leal is working on defining the role of Toll-like receptor 2-expressing B cells in the human mucosa. B cells isolated from mucosal tissues demonstrate a different phenotype and response to microbial antigens than those isolated from systemic tissues. These observations have been extended to define how mucosal B cell phenotype and function might be altered in inflammatory bowel disease. Her studies in this area are in collaboration with investigators in the Sections of Gastroenterology and Surgery, and include evaluating patient samples through immunological and immuno-epidemiological techniques.
Gibson III, Frank C., Ph.D.
Ph.D.: University of New Hampshire, Durham, NH
Postdoctoral training: Brigham and Woman’s Hospital and Harvard Medical School, Boston University School of Medicine
Dr. Gibson’s primary research interests focus into the mechanisms underlying microbial pathogenesis and gaining better insight into both host-specific and pathogen-specific activities/structures affecting diseases of the oral cavity. The principal organism studied in the Gibson lab is the anaerobic pathogen Porphyromonas gingivalis. Ongoing research interests in the Gibson lab include defining the properties of the capsular polysaccharide of P. gingivalis that influence disease caused by this organism. In addition, Dr. Gibson is interested in the defining the impact of chronic infections such as periodontal disease on the progression of systemic diseases including atherosclerotic cardiovascular disease. Genetic techniques, molecular approaches, as well as cell-based and animal modeling are routinely employed in the Gibson lab to better characterize novel host-pathogen interactions.
Gupta, Kalpana, M.D., M.P.H.
Medical School: State University of New York at Stony Brook
Residency training: New England Deaconess Medical Center
Fellowship training: University of Washington
Dr. Gupta is Chief, Section of Infectious Diseases at the Veterans Administration Boston Healthcare System, and Associate Professor of Medicine (proposed) at Boston University School of Medicine. Her primary research focus over the past decade has been on optimizing treatment regimens and prevention strategies for urinary tract infections (UTIs) in women. She is Chair of the IDSA UTI guideline update committee. She is currently PI of a multi-site NIH-funded randomized controlled trial of cranberry juice cocktail to prevent recurrent UTI in women and just completed a randomized trial of short course nitrofurantoin for treatment of acute cystitis in women. As a natural progression of her work on antimicrobial resistance in community-acquired UTIs, she is now embarking on a new research area, namely the evaluation of the prevalence and molecular epidemiology of MRSA infections in the veteran population.
Hamer, Davidson H., M.D.
Medical School: University of Vermont College of Medicine, Burlington, VT
Residency training: Washington Hospital Center, Washington, D.C.
Fellowship training: Tufts-New England Medical Center, Boston, MA
Primary appointment: Department of International Health Boston University School of Public Health
Dr. Hamer works at the Center for International Health and Development at the School of Public Health. He also directs the International Health Clinic within the Center for Infectious Diseases. He has a particular interest in tropical infectious diseases, with extensive field experience in malaria, HIV/AIDS, child survival studies, and antimicrobial resistance. Dr. Hamer is also an Adjunct Associate Professor of Nutrition at the Tufts University Friedman School of Nutrition Science and Policy, where he is involved in micronutrient interventions for prevention and treatment of infections. During the last five years, Dr. Hamer has worked closely with the Zambian National Malaria Control Centre, providing technical input on the development of a national malaria information system, in vivo efficacy studies of artemesinin-based combination therapy, and applied research on community-based effectiveness studies of antimalarial therapy.
Henderson, Andrew J. Ph.D.
Education: Ph.D., Biomedical Sciences, University of California, Riverside
Postdoctoral, Microbiology, Columbia University
Molecular events that regulate HIV expression: The primary focus of the Henderson lab is investigating how cellular signals regulate HIV-1 transcription and replication. Current projects include examining how signal transduction pathways impact HIV replication, including repression of provirus transcription and the establishment of latent cellular reservoirs as well as determining how HIV-1 influences cell function.
Horsburgh, C. Robert Jr., M.D., M.U.S.
Medical School: Case Western Reserve University School of Medicine
Residency training: Massachusetts General Hospital, University of Colorado Health Science Center
Fellowship training: University of Colorado Health Sciences Center, National Jewish Hospital
Dr. Horsburgh is the Chairman of the Department of Epidemiology at Boston University School of Public Health, where he teaches courses in the epidemiology of HIV/AIDS and the epidemiology of tuberculosis (TB). His clinical research interests include the epidemiology of TB, nontuberculous mycobacterial infections (NTM) and opportunistic infections in AIDS; clinical trials of therapies for TB, NTM and AIDS-OI; clinical trials design; mycobacterial vaccine trials and trial design; immune response to mycobacteria; and the effect of architectural design on health. Dr. Horsburgh is principal investigator for an NIH study of HIV and HCV coinfection, and program director for an NIH T32 Training grant for HIV-related clinical research.
Ingalls, Robin R., M.D.
Medical School: Harvard Medical School
Residency training: University Hospital/Boston University Medical Center
Fellowship training: Boston University School of Medicine
Dr. Ingalls’ research interests relate to the innate immune response to bacterial pathogens, with a particular interest in reproductive immunology and the pathogenesis of gonococcal and chlamydia infections. One major goal of her research is to identify the cellular receptors and bacterial ligands that are involved in the activation of mucosal epithelial cells during genital tract infections. Experimental models have been developed to examine the interaction of phagocytes and epithelial cells with N. gonorrhoeae and C. trachomatis as a means to understanding the pathogenesis of pelvic inflammatory disease; recently Dr. Ingalls has begun investigating the role of C. pneumoniae in atherosclerosis and inflammation.
Kanno, Mettassebia, M.D.
Medical School: Addis Ababa University Faculty of Medicine, Ethiopia
Residency training: Our Lady of Mercy Medical Center, New York Medical College
Fellowship training: Detroit Medical Center Wayne State University
Dr. Mettassebia Kanno is the Medical Director of the Center for Infectious Diseases (CID), which is the outpatient infectious disease practice of Boston Medical Center. She oversees clinical activity within the CID, including the STD program, the HIV clinic, and the ID clinic. Dr. Kanno brings over 8 years of clinic STD and STD/public health administrative expertise to the CID. She provides primary care to persons living with HIV, infectious diseases outpatient consultations, and STD care. She also attends on the inpatient medical service and provides infectious diseases consultative services at Boston Medical Center. Dr. Kanno is board certified in Internal Medicine and Infectious Diseases. She is interested in the epidemiology of gonorrhea and chlamydia in the STD and HIV clinics. Dr. Kanno’s other research interests include management of anal HPV infections (pre-malignant and anal cancers) and HPV vaccinology and therapeutics.
Klempner, Mark S., M.D.
Medical School: Cornell University Medical College
Residency training: Massachusetts General Hospital
Fellowship training: National Institutes of Health, National Institutes of Allergy and Infectious Disease
Dr. Klempner’s research includes investigations into the basic molecular biology and pathogenic mechanisms of the Lyme disease spirochete, Borrelia burgdorferi, patient-based clinical research on prevention, diagnosis and treatment of Lyme disease, and novel molecular methods for detecting, identifying and quantifying microorganisms. Recently his laboratory has cloned and characterized the oligopeptide transport (permease) system in borrelia and is currently investigating how borrelia adapts its nutrient capture to the particular environments that the bacteria encounters (e.g., tick, mouse, human). Using in vitro and in vivo models, Dr. Klempner’s laboratory is also studying the role of matrix metalloproteinases in the pathogenesis of Lyme disease. Dr. Klempner’s patient-based studies focus in two general areas: vaccine protection and post-treatment chronic Lyme disease. Dr. Klempner is currently investigating approaches to novel strategies to interrupt transmission from the vector.
With regard to the clinical studies on patients with post-treatment chronic Lyme disease, the Klempner research team published the results of a treatment trial, which determined that 90 days of antibiotics were not better than placebo and that evidence of persisting borrelial infection could not be found. They have recently demonstrated a lack of HLA haplotype association with persisting symptoms indicating that an autoimmune cause for persistent symptoms is less likely.
As part of an NSBRI/NASA funded initiative, his laboratory has begun the development of spectroscopic “fingerprinting” which can detect, identify, quantify, and discriminate between bacterial and fungal species in environmental and biological specimens.
In collaboration with investigators at the Photonics Center, the Klempner lab is pursuing surface enhanced Raman spectroscopy to identify microorganisms. Through a recent grant from the NIH this work has been extended to investigate the possible fingerprinting of bioterrorism agents.
In October 2003, Dr. Klempner was named Principal Investigator on a grant from the National Institutes of Health to build a National Biocontainment Laboratory at Boston University Medical Center. This laboratory, funded by a grant from the National Institute of Allergy and Infectious Diseases, is being created to study and protect the American public against emerging infectious diseases and agents of bioterrorism. Construction of the National Emerging Infectious Diseases Laboratories Institute is scheduled to begin in the first quarter of 2006 and recruitment of faculty for the Institute later that year.
Madico, Guillermo, M.D., Ph.D.
Medical School: Cayetano Heredia School of Medicine, Lima, Peru
Ph.D.: International Health, The Johns Hopkins University School of Hygiene and Public Health, Baltimore
Postdoctoral training: National Institute of Health, NIAID, LIR, Bethesda, MD, The Johns Hopkins University School of Medicine, Baltimore, MD, Boston University Medical Center, Boston, MA
Dr. Madico is involved in the development of PCRs for the detection and quantification of infectious diseases in clinical samples. His work centers on Chlamydia trachomatis (Ct), Chlamydia pneumoniae (Cp), Trichomonas vaginalis (Tv), Neisseria gonorrhoeae (Ng), and Francisella tularensis. He has developed and validated a new method for the quantification of Ct using asymmetric PCR (α-PCR) that strongly correlates with quantitative Ct culture, to examine the influence of organism load on disease transmission. Dr. Madico has developed diagnostic and quantitative PCRs to detect and differentiate all Francisella tularensis (Ft) subspecies in clinical samples and mice tissue. He is using quantitative PCR for Ft to study organism loads in tissues during infection.
Massari, Paola, Ph.D.
Ph.D. and Post-doctoral training: University of Naples “Federico II”, Naples, Italy and Chiron-Biocine, Siena, Italy
Dr. Massari’s main research interests are in the pathogenic bacteria Neisseria meningitidis, in particular regard to the mechanisms of immune adjuvanticity of neisserial porins and their involvement in modulation of apoptosis.
Her work with the Neisseria porin proteins has described their ability to modulate apoptosis by acting on mitochondria and to induce target cells survival after infection. In addition, Dr. Massari’s work demonstrated that Neisserial porins immune stimulatory ability is related to their interaction with TLR2 and TLR1, which is necessary to activate cells signaling in the target cells.
Montano, Monty, Ph.D.
Ph.D. and Postdoctoral training: Stanford University School of Medicine, Stanford, CA
Fellowship training: Stanford University School of Medicine, Stanford, CA, Harvard School of Public Health, Boston, MA
Dr. Montano’s laboratory investigates host-pathogen response during HIV-1 infection. Research initiatives include the identification and analysis of host genes and molecular mechanisms engaged during HIV-1 infection and transmission; interaction between host immune factors and muscle remodeling during HIV associated wasting; and transcriptional control and evolution of HIV-1 sequences. The laboratory utilizes tools in molecular virology, quantitative analysis of gene and protein expression, and genome-wide microarray analysis to characterize transcriptional profiles association with HIV-1 infection, transmission and pandemic spread.
Nicol, Marlynne Quigg, Ph.D.
Ph.D.: University of Edinburgh, Scotland
Postdoctoral training: University of Edinburgh, University of Glasgow, Scotland
Dr. Nicol’s research focuses on the effects of HIV infection on immune responses to pathogens in the lung. Current research projects, in collaboration with Drs. Skolnik and Ieong, examine TLR-mediated responses, as well as cytokine and chemokine networks. Her major research goal is to identify changes in HIV-infected cells that result in immune response deficits. This research uses both in vitro cell line models and patient-derived samples, focusing on alveolar macrophages, which are the first line of defense against invading pathogens in the lung.
Serrao, Richard A., M.D.
Medical School: UCLA School of Medicine
Residency training: Cedars-Sinai Medical Center (UCLA), Los Angeles
Fellowship training: Boston University Medical Center
Dr. Serrao is BUSM Assistant Professor of Medicine at the Boston VA Medical Center and focuses on clinical Infectious Diseases/Hospitalist Medicine and systems based management while attending on medicine, ID, medical consultation and outpatient HIV services for most of the year. He has directed the medical student general medicine ward clerkship, runs the Introduction to Clinical Medicine course and lectures frequently on infectious diseases topics. His research interests include HIV treatment strategies and clinical vaccine trials where he serves as principle investigator for the ongoing nationwide shingles prevention study.
Sulis, Carol A., M.D.
Medical School: Columbia University College of Physicians and Surgeons
Residency training: Roger Williams General Hospital, Brown University School of Medicine
Fellowship training: Boston University School of Medicine, National Institutes of Allergy and Infectious Diseases, National Institutes of Health
Dr. Sulis is Associate Professor of Medicine at Boston University School of Medicine and Director of Hospital Epidemiology at Boston Medical Center and the Jewish Memorial Hospital Rehabilitation Center. Her investigations include the assessment of the risk factors associated with the development of nosocomial bacteremia. She has participated in CDC-based studies to evaluate risk factors associated with nosocomial transmission of tuberculosis and hepatitis C.
Dr. Sulis is currently participating in NaSH, a CDC sponsored multi-site program studying methods to reduce unprotected exposures to blood and to minimize the incidence of vaccine-preventable illness among health care workers, and TRAPE, a multi-site, CDC/JCAHO sponsored study to assess surgical prophylaxis. She is active in the Surveillance Task Force, a citywide consortium of hospital epidemiologists studying bioterrorism preparedness and the efficacy of syndromic surveillance.
Sullivan, Meg, M.D.
Medical School: Loyola University Stritch School of Medicine
Residency training: Brigham and Women’s Hospital
Fellowship training: Johns Hopkins University
Dr. Sullivan is Assistant Professor of Medicine at Boston University School of
Medicine and staff physician in the Center for HIV/AIDS Care and Research (CHACR) in the Center for Infectious Diseases where she serves as primary and specialty care provider for HIV-infected patients and faculty mentor for fellows in Infectious Diseases. Dr. Sullivan is also the Associate Director of the Infectious Disease Fellowship Program. She also serves as a consultant to the High Risk OB Practice at Boston Medical Center where she co-manages HIV-infected patients in conjunction with a specialist in Maternal-Fetal Medicine. Dr. Sullivan sees all pre-conceptual counseling consults in the CHACR for HIV-infected discordant and concordant couples contemplating pregnancy. She is currently developing a protocol with members of the Department of Obstetrics and Gynecology for assisted reproduction services in HIV-infected couples.
Tandon, Richa, M.D.
Medical School: Jawaharlal Nehru Medical College, Belgaum, Karnataka, India
Residency training: St. Elizabeth Medical Center, Boston, MA
Fellowship training: Boston University Medical Center, Boston, MA
Dr. Tandon is a physician in the Center for Infectious Diseases where she serves as a primary and specialty care provider for HIV-infected patients. She is also a consultant at the High-Risk OB Clinic where she manages HIV-infected patients in conjunction with a specialist in maternal-fetal medicine. She also provides infectious diseases consultation services to patients at Radius Health Care. Dr. Tandon’s main area of clinical research interest is women’s health. She is currently studying anal abnormalities in HIV-infected women. She hopes the results of this research will help in developing guidelines for prevention in this patient population.
Thornton, David J., M.D.
Medical School: Stanford University School of Medicine
Residency training: Beth-Israel Deaconess Medical Center
Fellowship training: Boston Medical Center
Dr. Thornton is a staff physician at the Boston VA Healthcare System. He is medical director of the HIV clinics at these sites and serves as the fellowship coordinator at the VA. His research interests include the epidemiology of liver disease, bone disease, and viral resistance in patients with HIV infection.
Weir, Susan, Ph.D., M.P.H.
Ph.D.: Epidemiologic Science, School of Public Health, University of Michigan
M.P.H.: Hospital and Molecular Epidemiology, School of Public Health, University of Michigan
Dr. Weir works with Dr. Lee Wetzler developing a vaccine against tularemia. She prepares vaccine antigens and adjuvants. She helped establish the program for work with Biosafety Level-3 organisms that pose an aerosol hazard, such as F. tularensis. Dr. Weir is a specialist microbiologist in biological safety microbiology through the National Registry of Microbiologists.
Wetzler, Lee M., M.D.
Medical School: SUNY/Health Sciences Center at Syracuse
Residency training: University of Michigan Medical Center
Postdoctoral training: The Rockefeller University
Fellowship training: Boston University School of Medicine
Dr. Wetzler’s laboratory investigates innate and adaptive immunity and microbial pathogenesis, especially in regards to vaccine development. One major aspect of this work centers on the pathogenic Neisseria, Neisseria gonorrhoeae and Neisseria meningitidis. He has found that the major outer membrane protein of these organisms, the Neisserial porin PorB, can work as an immune adjuvant due to it recognition by the pattern recognition receptor TOLL-like receptor (TLR) 2. He has found that antigen presenting cells, including B cells, dendritic cells and macrophages, are activated by PorB in a TLR2 , TLR1 and MyD88 dependent manner, inducting upregulation of class II MHC, costimulatory molecule CD86 and other markers of activation. Moreover, MAPK signaling events are required for the upregulation of the expression of these markers, as well as production of pro-inflammatory cytokines. Moreover, using an in vivo peritoneal mouse model of inflammation, we have shown that both PorB and intact N. meningitidis induce a significant cellular infux and pro-inflammatory cytokine production, which is also TLR2 dependent. However, we also found that mast cells are activated during this process, which may be in a TLR2 independent manner, along with a significant influx of eosinophils, indicative of induction of a TH2 type cellular response. Studies are continuing to investigate the mechanisms of these phenomena.
We are also investigating the use of this TLR2 ligand, PorB, as a vaccine adjuvant using classic antigens like OVA and more relevant antigens like bacterial capsular polysaccharide. This work has also been extended to investigate the adjuvant activity and mechanism of immune stimulation of the B subunit of cholera toxin. We have found that CTB induces antigen presenting cell stimulation via the lipid raft ganglioside GM1 via induction of a cell-signaling program ending in NF-kB and CREB activation and gene transcription. This work is still on going.
Finally, a new major thrust of the Wetzler lab is investigating the immune response and natural history of Francisella tularensis pulmonary infection in mice and using this data to aid in developing vaccines towards this potential bio-terrorist agent. We have found that using PorB as an adjuvant and Francisella LPS as an atigne, we can enhance protection in these mice, which is likely due to induction of antibodies and improved immunity (potentially both innate and adaptive immunity. It appears that induction of IL-1beta may be more associated with survival bith during natural infection and after vaccination, while IL-6 and IL-17 may have the opposite effect, being more associated with death after pulmonary infection. Finally we have recently found that induction of bronchial associated lymphoid tissue (BALT) after vaccaitnion also appears to be associated with protection. These iBALT structures are long lasting and may be due to persistent antigen stimulation, which we are currently investigating.
Yu, Catherine, M.D.
Medical School: University of Miami Miller School of Medicine
Residency training: Baystate Medical Center, Western campus of Tufts University School of Medicine
Fellowship training: University of Massachusetts Medical Center
Dr. Yu is an Attending Physician at Boston Medical Center and member of the Section of Infectious Diseases. Her work has included neonate cytokine and inflammatory responses to inactivated Herpes Simplex Virus type 1, the potential role of human Toll-Like Receptors (TLR) in these responses, and an outbreak investigation of gastroenteritis at a local central Massachusetts college. She has also been a contributor to the Manual of Intensive Care Medicine, 4th ed. (editors Richard S. Irwin and James M. Rippe). She currently cares for HIV-infected patients in the Center for Infectious Diseases and consults on infectious disease issues in patient care at the Jewish Memorial Hospital Rehabilitation Center.
